The National Cancer Institute is soliciting applications for the reissuance of its Clinical Proteomic Tumor Analysis Consortium (CPTAC) program. CPTAC will support broad efforts focused on several cancer types to explore further the complexities of cancer proteomes and their connections to abnormalities in cancer genomes. In addition, the potential of proteomic and proteo-genomic approaches will be explored in translational research focused on clinically-relevant problems, such as the ability to predict which treatments are likely to be effective against a specific patient's tumor.
The Funding Opportunity Announcements are:
- Proteome Characterization Centers (PCCs, to be supported under RFA-CA-15-021), Proteogenomic Translational Research Centers (PTRCs, to be supported under RFA-CA-15-022) , and Proteogenomic Data Analysis Centers (PGDAC, to be supported under RFA-CA-15-023) that will conduct integrative analyses of data across the entire proteomes and genomes of cancer types of focus to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level.